Xu L C, Nakayama M, Harada K, Nakayama H, Tomiguchi S, Kojima A, Takahashi M, Arano Y
Faculty of Pharmaceutical Sciences, Kumamoto University, Japan.
Nucl Med Biol. 1998 Apr;25(3):295-303. doi: 10.1016/s0969-8051(97)00208-4.
Both N,N'-ethylene bis(benzohydroxamamide) [(C2(BHam)2)] and N,N'-propylene bis(benzohydroxamamide) [(C3(BHam)2)] were designed as new thiol-free chelating molecules for 99mTc radiopharmaceuticals. Synthetic procedures using oxadiazoline intermediates were developed for C2(BHam)2 and C3(BHam)2. Both C2(BHam)2 and C3(BHam)2 formed 99mTc complexes with high yields over a wide pH range (pH 3-12) at room temperature. Complexation yields of over 95% were achieved at ligand concentrations as low as 2.5 x 10(-6) M. Reversed-phase HPLC analyses indicated that both C2(BHam)2 and C3(BHam)2 formed 99mTc complexes as single species with stabilities much higher than those of 99mTc-BHam. Selective complex formation of 99mTc with the two ligands was observed in the presence of human IgG. No decomposition with low protein binding were demonstrated when the two 99mTc complexes were incubated in murine plasma. Although further structural studies are required, these findings implied that the Ham-based tetradentate ligands would serve as new chelating molecules for 99mTc radiopharmaceuticals.
N,N'-亚乙基双(苯甲酰羟肟酸)[C2(BHam)2]和N,N'-亚丙基双(苯甲酰羟肟酸)[C3(BHam)2]均被设计为用于99mTc放射性药物的新型无硫醇螯合分子。已开发出使用恶二唑啉中间体合成C2(BHam)2和C3(BHam)2的方法。在室温下,C2(BHam)2和C3(BHam)2在较宽的pH范围(pH 3 - 12)内均能以高产率形成99mTc配合物。在配体浓度低至2.5×10(-6) M时,配合产率达到95%以上。反相高效液相色谱分析表明,C2(BHam)2和C3(BHam)2均以单一物种形式形成99mTc配合物,其稳定性远高于99mTc - BHam。在人IgG存在下,观察到99mTc与这两种配体的选择性配合物形成。当两种99mTc配合物在小鼠血浆中孵育时,未显示出低蛋白结合导致的分解。尽管需要进一步的结构研究,但这些发现表明基于Ham的四齿配体将作为99mTc放射性药物的新型螯合分子。